Ken VanLuvanee, PresidentFacet Life Sciences stands as the perfect support for early-stage companies, helping them chart a clear and strategic path forward from drugs, biologics, and devices. This regulatory affairs and development advisor exclusively works with smaller companies to truly support them at every stage — from investor acquisition to bringing lifesaving innovations to patients.
The company is experienced in all therapeutic areas, with specialties in radiopharmaceuticals, psychedelics, ophthalmics, CNS, and oncology. Its broad scientific knowledge base combined with clinical support, statistical analysis, commercialization strategies and investor engagement enable it to provide comprehensive end-to-end support focused exclusively on smaller companies and non-profit research centers.
Facet’s expertise and experience positions it as an advisory powerhouse that helps companies turn their R&D efforts into lifesaving innovations, aligning with FDA requirements and company goals.
“We look at the science, the data that supports that science, and the ability to tell a compelling story about what that data truly translates into,” says Ken VanLuvanee, president.
This time-tested model drives Facet’s excellence. Its approach presents regulators with a clear, data-backed case that meets safety and efficacy standards—one that regulators can confidently support in bringing a therapy to the clinic or market.
Facet helps clients move efficiently from discovery to development, then to market or divestiture at any stage. It integrates financial and commercial insights to drive long-term value at each development stage by applying health economics research (HEOR) to align clinical trials with market potential, ensuring a client’s efforts are in line with market and investor interests as the foundation for either divestiture or product launch.
Facet helps clients prepare Investigational New Drug (IND) applications and guides their interactions with the FDA from pre-IND meeting to marketing approval/launch. Its expertise in chemistry, manufacturing and controls (CMC), nonclinical, clinical, and regulatory ensures a complete solution as a product progresses through development. This scientific foundation is further strengthened by statistical clinical trial optimization, enabling companies to refine study designs, shorten trial durations, and reduce costs. The goal is to simplify the entire process for biotech firms, driving reductions in time, resource, and expense.
-
We look at the science, the data that supports that science, and the ability to tell a compelling story about what that data truly translates into
Facet helps clients move efficiently from discovery to development, then to market or divestiture at any stage. It integrates financial and commercial insights to drive long-term value at each development stage by applying health economics research (HEOR) to align clinical trials with market potential, ensuring a client’s efforts are in line with market and investor interests as the foundation for either divestiture or product launch.
By tying investment strategies to development and commercialization expertise, Facet ensures decisions that are both scientifically and commercially sound.
One example involved a small biotech firm developing a promising compound. The client faced significant challenges, including limited resources, regulatory uncertainty and an unclear market path. Facet stepped in to assemble a team of regulatory, statistical and market experts who analyzed the available data and identified the most viable patient population. Through a structured evaluation of FDA approvability, market potential and patient availability, Facet helped the client determine the best indication to pursue.
Facet then developed a streamlined program to complete nonclinical testing and progress to clinical trials. Over four months, it guided the client in refining their focus, addressing regulatory gaps, conducting a pre-IND meeting with the FDA, and successfully submitting an IND application. This resulted in the biotech firm receiving FDA green light to proceed with clinical trials in record time.
The company’s accomplishments have led it into emerging therapeutic areas with no previous regulatory pathways where Facet works collaboratively with FDA to determine agreed novel regulatory programs for these evolving areas. Facet’s continued growth reinforces its position as a trusted partner for small biotech companies striving to bring life-changing therapies to market.
Navigating Regulatory Complexity in Emerging Biotech Development
Regulatory strategy in life sciences has shifted from a compliance exercise to a defining factor in whether a therapy reaches patients at all. Executives overseeing development programs face a landscape where evolving FDA expectations, compressed funding cycles and heightened scrutiny around evidence generation intersect. Traditional development models, built for large pharmaceutical organizations with extensive resources, often fail to translate to emerging biotech environments where capital efficiency and speed carry equal weight to scientific rigor.
Uncertainty in regulatory pathways has become a central challenge. Agencies continue to refine guidance across biologics, personalized therapies and novel modalities, creating ambiguity in how evidence packages should be constructed. Early-stage companies, in particular, struggle to determine how much data is sufficient at each milestone. Overbuilding evidence can delay timelines and exhaust capital, while under-preparing risks rejection or costly rework. The consequence is a persistent tension between caution and progress that requires experienced judgment rather than procedural adherence.
Effective regulatory leadership begins with clarity around business intent. Development pathways differ significantly depending on whether a company aims to secure early proof of concept for partnership or carry a product through full approval and commercialization. Aligning regulatory decisions to that objective ensures that every study, interaction and submission contributes directly to the intended outcome rather than following a generalized pathway. This alignment reduces unnecessary work and avoids missteps that cascade into later stages of development.
Early-stage decision-making holds disproportionate influence over program success. Conversations with regulators, trial design choices and endpoint selection create downstream implications that can alter timelines by years. Programs that engage in disciplined planning at inception are better positioned to avoid redundant studies and reposition quickly when data evolves. The ability to interpret emerging results and adjust strategy without compromising regulatory acceptance has become a defining capability in modern development.
Scientific narrative also plays a critical role. Regulatory agencies ultimately evaluate whether a therapy is safe, effective and meaningful for patients. Translating complex data into a coherent argument that demonstrates these outcomes requires more than technical execution. It demands an understanding of how evidence is perceived, how risk is contextualized and how to present findings in a way that aligns with regulatory expectations. Companies that succeed in this area tend to focus not only on generating data but on ensuring that the data clearly supports a compelling case for approval.
Continuity across development stages further distinguishes effective programs. Fragmentation between regulatory, clinical and commercial planning often leads to misalignment, particularly when commercialization considerations are deferred. Early visibility into market positioning, patient populations and payer expectations informs better scientific and regulatory choices. Organizations that integrate these perspectives from the outset are more likely to pursue development paths that balance feasibility, value and long-term viability.
Facet Life Sciences exemplifies this integrated approach by focusing on emerging biotech companies and aligning regulatory strategy closely with business objectives. It brings an experienced team that guides clients through regulatory, clinical and manufacturing considerations while emphasizing efficient evidence generation. Its approach centers on identifying opportunities to streamline development, often enabling clients to avoid unnecessary studies and reduce both time and cost. The firm supports programs from early development through submission while maintaining continuity through data interpretation and strategic adjustments. By combining regulatory insight with scientific framing and commercial awareness, it positions itself as a strong partner for companies aiming to advance therapies efficiently without compromising quality.
...Read more
Regulatory Services Info
Q1
What has positioned Facet Life Sciences among Top Regulatory Services Providers?
Deep regulatory expertise and a science-focused consulting approach have helped Facet Life Sciences gain recognition among Top Regulatory Services Providers. The company supports pharmaceutical, biotechnology and medical device organizations through regulatory strategy, submission support and compliance guidance across multiple stages of product development. Its ability to combine scientific understanding with evolving global regulatory requirements has strengthened its position within regulatory services providers. This integrated approach enables the company to support organizations navigating increasingly complex approval and compliance processes.
Q2
How does Facet Life Sciences differentiate its regulatory consulting approach?
Facet Life Sciences emphasizes tailored regulatory guidance designed around the specific development goals and product requirements of each client. Instead of applying standardized consulting models, the company structures its regulatory services providers capabilities around strategic planning, scientific communication and lifecycle regulatory support. Its teams work across development stages to help organizations prepare submissions, manage regulatory interactions and maintain compliance alignment. This customized and development-focused methodology gives Facet Life Sciences a differentiated presence within regulatory services providers.
Q3
How does the company support product development and regulatory submissions?
Successful product development depends on clear regulatory planning and accurate documentation. Facet Life Sciences supports regulatory services providers through submission preparation, regulatory strategy development and compliance management activities designed to improve development efficiency and review readiness. Its expertise includes helping organizations address regulatory expectations across clinical, manufacturing and post-approval environments. By supporting structured regulatory communication and documentation quality, the company contributes to more streamlined development progress.
Q4
What role does scientific expertise play in Facet Life Sciences’ services?
Scientific knowledge remains central to the company’s regulatory consulting model. Facet Life Sciences applies regulatory science, technical understanding and industry experience to strengthen regulatory services providers capabilities across pharmaceutical and life sciences sectors. Its teams support organizations that require detailed regulatory interpretation and scientifically grounded submission strategies. This expertise-driven approach enables the company to address complex compliance and approval challenges while supporting informed regulatory decision-making.
Q5
How do regulatory services providers create value through Facet Life Sciences?
Regulatory value comes from improving development clarity, submission quality and compliance confidence. Facet Life Sciences delivers regulatory services providers support that helps organizations strengthen regulatory readiness, reduce submission inefficiencies and improve communication with health authorities. Its consulting capabilities also contribute to better coordination between scientific, clinical and regulatory functions during development activities. This balance between regulatory precision and strategic guidance increases the long-term value of the company’s services.
Q6
Why is Facet Life Sciences relevant to the future of regulatory consulting?
Life sciences organizations continue to face expanding global regulations, evolving compliance expectations and increasingly specialized product development pathways. Facet Life Sciences contributes to this changing environment through regulatory services providers capabilities focused on scientific expertise, strategic regulatory planning and development support. Its emphasis on adaptable regulatory guidance aligns with industry priorities surrounding compliance efficiency and accelerated development timelines. As regulatory frameworks continue to evolve across healthcare sectors, the company remains relevant to the future of regulatory consulting.
